AARD Stock Summary and Trading Ideas (Aardvark Therapeutics | NASDAQ:AARD)

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Aardvark Therapeutics trades on the NASDAQ stock market under the symbol AARD.

As of June 26, 2026, AARD stock price declined to $4.79 with 1,361,647 million shares trading.

AARD has a beta of 4.54, meaning it tends to be more sensitive to market movements. AARD has a correlation of 0.21 to the broad based SPY ETF.

AARD has a market cap of $104.50 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that AARD belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.

AARD has underperformed the market in the last year with a return of -68.9%, while SPY returned +21.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in AARD shares. However, AARD has outperformed the market in the last 3 month and 2 week periods, returning +35.3% and +31.6%, while SPY returned +11.3% and -0.9%, respectively. This indicates AARD has been having a stronger performance recently.

AARD support price is $4.75 and resistance is $5.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AARD shares will trade within this expected range on the day.